Tracer library / [177Lu]Lu-DOTA-EB-TATE

[177Lu]Lu-DOTA-EB-TATE

Also written as [Lu-177]Lu-DOTA-EB-TATE; Lu-177-DOTA-EB-TATE
Radionuclide
Lu-177 t½ 9584.6 min
Modality
Therapy
Production route
—
Stage
—
Syntheses indexed
0
Neuroendocrine neoplasmsDosimetry and biodistribution studiesPeptide receptor radionuclide therapy

What it is

Compound class
Somatostatin analogue (radiolabelled peptide, DOTA-conjugated, Evans blue-modified for albumin binding)
Target / mechanism
Somatostatin receptor binding, with Evans blue moiety for albumin binding to prolong blood residence time PMID 33452632
Clinical application
Peptide receptor radionuclide therapy in patients with somatostatin receptor-positive progressive disease PMID 33452632
Theranostic pair
—

Published syntheses

No synthesis has been parsed for this agent yet.

Clinical literature

Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.

  1. Evaluation of Safety, Biodistribution, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177 Lu-DOTA-EB-TATE With and Without Amino Acid Infusion.
    2023 · Clin Nucl Med · Clinical study
  2. Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC.
    2021 · Eur J Nucl Med Mol Imaging · Clinical study

Need this precursor?We can point you to suppliers for [177Lu]Lu-DOTA-EB-TATE, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty.
Ask a question